Enoxaparin for 7 days was better than unfractionated heparin for 2 days for reducing death and MI but not bleeding in STEMI

September 2006
ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p30
Academic Journal
The article presents information on the usage of the drug enoxaparin and its comparison with unfractionated heparin as adjunctive therapy for reducing death in patients with ST-elevation myocardial infarction (STEMI). The clinical trials were conducted on 20, 506 patients. It was found that in patients with STEMI, 7 days of enoxaparin provided better results than 2 days of unfractionated heparin as adjunctive therapy with fibrinolysis for reducing nonfatal myocardial infarction and death.


Related Articles

  • Thrombolysis, With or Without Heparin, During the First Nine Weeks After Acute Myocardial Infarction. Pickering, W.; Brozovic, M.; Dancy, M.; Cohen, H. // Clinical & Applied Thrombosis/Hemostasis;Jul1997, Vol. 3 Issue 3, p183 

    The duration and characteristics of fibrinolytic "shut-down" were studied in 40 patients serially for a 9-week period after acute myocardial infarction (AMI). Patients were randomized into four equal groups to receive streptokinase (SK). SK plus heparin (SK + H), recombinant tissue plasminogen...

  • fibrinolysis. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p308 

    An encyclopedia entry for the term "fibrinolysis" is presented. It refers to the breakdown of the main component of any blood clot called fibrin. This component is a stingy protein found in blood as the end product of coagulation. It cites the disorders which can be treated by drugs that achieve...

  • Clopidogrel Bisulfate In ST-Segment Elevation Myocardial Infarction: A Viewpoint by Deepak L. Bhatt. Bhatt, Deepak L // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 6, p415 

    Ramipril is an oral, non-sulfhydryl ACE inhibitor thought to act in the renin-angiotensin-aldosterone system to decrease vasopressor activity, aldosterone secretion, and bradykinin degradation.Ramipril is generally well tolerated and effective in the treatment of patients aged ≥55 years at...

  • Reperfusion Paradox in ST-Segment Elevation Myocardial Infarction. Armstrong, Paul W.; Boden, William E. // Annals of Internal Medicine;9/20/2011, Vol. 155 Issue 6, p389 

    A transformation in ST-segment elevation myocardial infarction (STEMI) care in the United States has unfolded. It asserts superior reperfusion with primary percutaneous coronary intervention (PPCI) over fibrinolysis on the basis of studies showing the former method to be superior for reperfusion...

  • COMMENTARY: Fondaparinux reduced death or reinfarction in acute ST-segment elevation myocardial infarction. Borzak, Steven // ACP Journal Club;Sep/Oct2006, Vol. 145 Issue 2, p29 

    The article comments on the study related to the use of the drug fondaparinux to treat patients with acute ST-segment elevation myocardial infarction (STEMI). In the study fondaparinux was found useful in reducing death. These trials support the use of anticoagulant therapy in patients with...

  • Current Drug Treatment Strategies for Disseminated Intravascular Coagulation. de Jonge, E.; Levi, M.; Stoutenbeek, C.P.; van deventer, S.J.H. // Drugs;Jun1998, Vol. 55 Issue 6, p767 

    Disseminated intravascular coagulation (DIC) can be caused by a variety of diseases. Experimental models of DIC have provided substantial insight into the pathogenesis of this disorder, which may ultimately result in improved treatment. Disseminated coagulation is the result of a complex...

  • EPITHET: Clot-busting drug helps restore perfusion, fails to reduce size of infarct. Raible, Eric // Cardiology Today;Apr2008, Vol. 11 Issue 4, p26 

    The article reports the results of a clinical trial for recombinant tissue plasminogen activator alteplase, a clot-busting drug. Findings showed that the drug was effective in improving outcomes in certain cardiac patients, but failed to reduce the size of infarction. Geometric mean infarction...

  • TRA 2°P-TIMI 50 Results. Alexander, Lori // MD Conference Express;Oct2012, p25 

    The article discusses the findings from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction (MI) 50 (TRA 2°P-TIMI 50) clinical trial. Medical director Benjamin M. Scirica has presented the efficacy and safety of...

  • Changes in Fibrinogen After rt-PA Administration. Carr, Justine Meehan; Bovill, Edwin G.; Tracy, Russell P.; Mankowski, Martin; Mann, Kenneth G.; McDonagh, Jan // Clinical & Applied Thrombosis/Hemostasis;Winter1996, Vol. 2 Issue 1, p43 

    Among patients participating in the TIMI-II protocol, there was a variability in the fibrinolytic response to recombinant tissue plasminogen activator (rt-PA). A cohort of 20 TIMI-II patients was selected for detailed study because their responses to rt-PA varied widely in the degree of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics